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Abstract
Gap junctions comprise arrays of intercellular channels formed by connexin proteins and provide for the direct
communication between adjacent cells. This type of intercellular communication permits the coordination of cellular
activities and plays key roles in the control of cell growth and differentiation and in the maintenance of tissue homoeostasis.
After more than 50 years, deciphering the links among connexins, gap junctions and cancer, researchers are now beginning
to translate this knowledge to the clinic. The emergence of new strategies for connexin targeting, combined with an
improved understanding of the molecular bases underlying the dysregulation of connexins during cancer development, offers
novel opportunities for clinical applications. However, different connexin isoforms have diverse channel-dependent and
-independent functions that are tissue and stage speciﬁc. This can elicit both pro- and anti-tumorigenic effects that engender
signiﬁcant challenges in the path towards personalised medicine. Here, we review the current understanding of the role of
connexins and gap junctions in cancer, with particular focus on the recent progress made in determining their prognostic and
therapeutic potential.
Introduction
Connexins are integral membrane proteins that form chan-
nels between adjacent cells and thereby permit the bidir-
ectional cytosolic exchange of ions, metabolites and
secondary messengers ( < ~ 1200 Da) (Fig. 1a) [1]. These
channels assemble into distinct plasma membrane domains
termed gap junctions (Fig. 1b) [1]. Gap junction inter-
cellular communication (GJIC) plays essential roles in
tissue homoeostasis and regulation of cell growth and dif-
ferentiation [2]. In addition, connexins form functional
channels at the non-junctional areas of the plasma mem-
brane (Fig. 1) [3]. These so-called hemichannels provide a
communication pathway between the intracellular and
extracellular milieus that is important in autocrine and
paracrine signalling [3]. Connexins also possess signiﬁcant
channel-independent roles, including the one as signalling
hubs, which may occur at the plasma membrane, in the
cytoplasm or even in the nucleus [2].
The human connexin protein family contains 21 mem-
bers, of which the most widely studied is connexin 43
(Cx43) [2]. A large body of experimental evidence suggestsThese authors contributed equally: Trond Aasen, Edward Leithe
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that connexins are causally involved in cancer pathogenesis,
possessing both pro- and anti-tumorigenic functions (see the
below section and recent reviews [2, 4]). Signiﬁcant
advances have been made towards understanding how
connexins can act as either tumour suppressors or tumour
promoters depending on the isoform, cancer stage and tis-
sue. In addition to the emerging prognostic value of con-
nexins in cancer, several studies indicate that connexin
targeting might have considerable therapeutic implications
[5, 6]. This review provides an overview of our current
understanding of the role of connexins in cancer, with
emphasis on their prognostic and therapeutic potential.
Complex roles of connexins in cancer
Connexins as tumour suppressors
The idea that GJIC regulates tumour growth was proposed
by Loewenstein and Kanno more than 50 years ago in a
seminal ex vivo study, in which they demonstrated the loss
of electrical coupling occurring in rat liver tumours [7].
Since then, several connexin knockout mouse models have
supported the notion that connexins have tumour-
suppressive functions (reviewed in ref. [2]), notably Cx32
(multiple organs), Cx43 (breast and lung) and Cx26
(breast). Cancer cells often display a loss of GJIC due to the
dysregulation of connexin expression at multiple levels
(Fig. 2). At the transcriptional level, the reduced connexin
expression in tumours involves transcriptional and epige-
netic mechanisms such as promoter methylation [8–11]. At
the post-transcriptional level, the suppression of connexin
expression can be due to connexin-targeting microRNAs
[12, 13]. At the protein-synthesis level, internal translation
of N-terminally truncated forms of Cx43 [14–16] has
recently been described to regulate connexin membrane
targeting [14], and Smad3/ERK-dependent repression of
this process was reported to reduce Cx43 gap junctions
during epithelial-to-mesenchymal transition [17]. At the
post-translational level, many growth factors, oncogenes
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Fig. 1 Connexins, connexons and gap junctions. a Connexins are
tetraspanning integral membrane proteins with cytosolic C and N
termini. Six connexins oligomerize to form a connexon. At the plasma
membrane, the connexon can dock head-to-head with a connexon in an
adjacent cell to form a gap junction intercellular channel. b Bio-
synthesis, intracellular trafﬁcking and degradation of connexins. (1)
Connexins are cotranslationally inserted into the endoplasmic reticu-
lum. (2) A subpool of newly synthesised connexins undergo endo-
plasmic reticulum-associated degradation. (3) During their trafﬁcking
to the plasma membrane, connexins oligomerise into connexons. (4)
After their arrival at the plasma membrane, the connexons can dock
with connexons from adjacent cells to form gap junction channels. (5)
Connexons may also form functional channels at the non-junctional
areas of the plasma membrane (also known as hemichannels). (6) Gap
junction endocytosis results in the formation of a connexosome (also
known as annular gap junction). (7) The connexosome may be
degraded by autophagy. (8) Alternatively, the connexosome may
change its morphology to that of a connexin-enriched multivesicular
endosome in a process that is associated with the fusion between the
connexosome and early endosomes. (9) Connexins are sorted from
early endosomes to lysosomes via late endosomes. (10) Under certain
conditions, endocytosed connexons may undergo recycling to the
plasma membrane. Hemichannels also undergo endocytosis and
recycling, but their endocytic and recycling pathways are poorly
characterised (question marks). (11) Multivesicular endosomes can
fuse with the plasma membrane to secrete exosomes containing con-
nexons. (12) Microvesicles containing connexons can be formed by
the outward budding of the plasma membrane
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and tumour-promoting chemicals are potent inducers of
Cx43 phosphorylation, which is often associated with the
inhibition of GJIC [18] and increased Cx43 ubiquitination,
endocytosis and degradation [19].
In accordance with the notion that connexins might act as
tumour suppressors, the ectopic expression of connexins in
cancer cells often partly restores growth control (e.g. refs.
[20–25]) and differentiation potential (e.g. refs. [26–28],
reviewed in ref. [2]). Conversely, the experimental
depletion of connexins may result in more aggressive cancer
cell growth [29]. In addition to their role in modulating cell
proliferation [30], connexins can either promote or prevent
cell death by apoptosis [31]. Such effects may be due to the
gap junction-mediated intercellular passage of survival or
death signals such as Ca2+, IP3 and cAMP [2, 32–34].
Moreover, hemichannels may exchange proapoptotic and
survival factors between extracellular and intracellular
environments [35].
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There is increasing evidence that connexins can suppress
the growth of cancer cells through channel-independent
mechanisms [22, 30, 36–39] (Fig. 3). For example, the
ectopic expression of the intracellular C terminus (CT) of
Cx43 can in some cases inhibit cell proliferation to a similar
extent as full-length protein [24]. Connexins may also mod-
ulate the activity of some of their partners by affecting their
cellular location, as proposed by Skp2 for Cx50 [40], β-
catenin for Cx43 [38], discs large homologue 1 (Dlgh1) for
Cx32 [41] and Cx43 [42], or by other mechanisms, such as
the recruitment of Src together with its endogenous inhibitors
CSK and PTEN resulting in a switch from the active to
inactive conformation of c-Src [43] (Fig. 3). Because con-
nexins present a low level of homology within their CT
sequences, the channel-independent regulation of cell growth
is expected to vary considerably among different isoforms.
Connexins as promoters of invasion and metastasis
When assessing the role of connexins in cancer pathogen-
esis, we must consider that their ability to act as tumour
suppressors can vary considerably among tissue types and
cancer stages, as well as among connexin isoforms [2].
Furthermore, there is growing evidence that some connexin
isoforms are protumorigenic under certain conditions. For
example, connexins can promote the migration and invasion
of tumour cells [44, 45]. In addition, connexins can form
heterologous gap junctions between tumour cells and
endothelial cells to facilitate intravasation and extravasation
[46–49]. Connexins can also nurture metastatic growth and
may promote resistance to cancer treatments [50–53]. In
accordance with this notion, a recent study demonstrated
that brain metastatic cancer cells establish gap junctions
with astrocytes to promote tumour growth and chemore-
sistance [50].
Connexins and cancer stem cells
Emerging experimental evidence indicates that connexins
play important roles in cancer stem cell (CSC) biology.
Malignant glioma stem cells (GSCs) express very low levels
of Cx43, and GSC stemness is reduced by its transfection
with Cx43 or treatment with peptides containing sequences
of Cx43 that interact with c-Src (Cx43 mimetic peptides)
[54, 55]. A recent work has found that the expression levels
of Cx43 and Cx46 were increased and reduced, respec-
tively, during GSC differentiation and that targeting of
Cx46 compromises GSC maintenance [56]. While Cx43 is
almost absent in liver CSCs [57], the accumulation of
cytoplasmic Cx32 has been associated with metastasis and
enhanced self-renewal of CSCs in human HuH7 hepatoma
cells [58]. Some subtypes of breast cancer cells positive for
the putative CSC marker CD44 express Cx43 [59, 60].
Moreover, Cx43 clearly plays a subtype-dependent role in
breast cancer [61]. In triple-negative breast cancers, Cx26
was shown to be upregulated in CSC population, in which it
forms a complex with NANOG and focal adhesion kinase to
drive self-renewal (Fig. 3) [62].
Overall, connexins can be both anti- and pro-tumori-
genic, acting via processes that include the regulation of
CSCs, and this depends on the connexin isoform and tissue
type. Understanding this complexity is the key to the
development of new and efﬁcient therapies.
Prognostic value of connexins in cancer
A number of studies suggest that connexins can be inde-
pendent tumour markers predicting both better and worse
prognoses. Further insights into this seeming contradiction
have been provided by recent analytical tools for public
databases. The Pathology Atlas within the Human Protein
Atlas database (https://www.proteinatlas.org/pathology)
includes an open-access database (retrieved from The
Fig. 2 Dysregulation of connexins in cancer: therapeutic opportunities.
Multiple stages of connexin life cycle are subject to dysregulation
during cancer progression, as exempliﬁed by GJA1 (Cx43). (1)
Transcription: connexin expression is often reduced (but sometimes
increased) in human tumours at the mRNA expression level, of which
multiple pathways are therapeutic targets (text highlighted in red for
key targets), including transcription factor activity and epigenetic
silencing by histone acetylation and promoter methylation (promoter
region in green, with C and M illustrating the non-methylated and
methylated sites, respectively; blue, some important transcription
factors regulating Cx43 expression). Histone acetylation can be
modiﬁed by targeting histone acetyltransferase enzymes (HATs) or
histone deacetylases (HDACs), typically promoting and repressing
transcription, respectively. Transcriptional silencing due to promoter
hypermethylation by DNA methyltransferase enzymes (DNMTs) may
also be amenable to therapeutic intervention leading to the restoration
of GJIC. (2) mRNA regulation: mRNA stability and translation is
subject to regulation by multiple cancer-associated microRNAs.
Moreover, alternative translation initiation, resulting in the synthesis of
truncated forms of Cx43, might regulate Cx43 and have important
implications for its dysregulation in cancer. This process is regulated
by key cancer signalling pathways such as mTOR and Mnk1/2 and is
altered during pathological conditions such as hypoxia. Truncated
forms of Cx43, notably the 20-kDa form named GJA1–20k, may be
important for the efﬁcient targeting of Cx43 to the membrane. Indeed,
Smad3/ERK-dependent repression of GJA1–20k was recently shown
to reduce Cx43 gap junctions during epithelial-to-mesenchymal tran-
sition (EMT). (3) Post-translational regulation: connexins frequently
display an aberrant localisation in cancer cells. Phosphorylation and
other multiple post-translational events, occurring mainly at their C
terminus, regulate connexin trafﬁcking and stability at the plasma
membrane. Cx43 is regulated by several kinases that are frequently
overactivated or overexpressed during cancer development and sus-
ceptible to pharmacological inhibition, such as mitogen-activated
protein kinase (MAPK), protein kinase C (PKC), protein kinase A
(PKA), cdc2/cyclin B and v-src/c-src. Cx43 is also regulated by
acetylation, ubiquitination and SUMOylation
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Cancer Genome Atlas (TCGA)) containing correlation
analyses based on mRNA expression levels with respect to
the clinical outcome for 17 major cancer types and almost
8000 cancer patients [63]. Those mRNAs encoding con-
nexins identiﬁed to have a highly signiﬁcant prognostic
value (P < 0.001) in any of these cancer types are sum-
marised in Table 1. Notably, GJA1 (encoding Cx43) is
featured in the list of 20 genes most signiﬁcantly associated
with an unfavourable prognosis in stomach cancer. Indeed,
for most connexins and cancer types, high levels of con-
nexin mRNA expression are associated with a poor prog-
nosis. It is also notable that the mRNA expression of a
given connexin-encoding gene can be both favourable and
unfavourable, depending on the type of tumour (Table 1).
Different connexins can also have differing prognostic
prediction results for the same type of tumour (e.g. Cx26 vs
Cx32 in renal cancer). The sub-classiﬁcation of cancers is
also relevant. For example, the Kaplan–Meier Plotter tool
(http://kmplot.com/analysis) suggests that high levels of
Cx43 mRNA are associated with good and poor prognoses
in oestrogen receptor-positive and -negative breast cancer
subtypes, respectively [64].
Several speciﬁc studies have also reported a correlation
between connexin mRNA levels and survival or phenotypic
features. For instance, high levels of Cx43 mRNA in glioma
tumours have been correlated with poor survival [65].
Expression of connexin mRNA in the surrounding tissue
may also correlate with a speciﬁc tumour phenotype or
behaviour. For example, in melanoma, the increased
expression of Cx26 and Cx30 at the mRNA level in the
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Fig. 3 Interactions between connexins and proteins that affect tumour
growth and migration. Examples of proteins that interact with speciﬁc
regions of connexins and may act as therapy targets. a The interaction
between Cx43 and tubulin is involved in the regulation of cell
migration. Similar mechanisms have been proposed for other proteins
associated with the cytoskeleton, such as cadherins, catenins, vinculin,
ZO-1 and drebrin. In addition, Cx43 may compete with the tubulin–
Smad2/3 interaction causing Smad2/3 release. Cx43 binds to c-Src and
its endogenous inhibitors CSK and PTEN, promoting c-Src inhibition.
Cx43, by interacting with β-catenin, prevents the transcriptional
activity of β-catenin in the nucleus, where it regulates the expression of
genes involved in promoting cell malignancy. A similar sequestration
mechanism may occur with drebrin, ezrin or ZO-1. These proteins, and
many others such as Nedd4, also have important roles in regulating
Cx43 gap junction plaques, which inﬂuence GJIC and therefore may
have therapeutic potential. b Cx26 has been proposed to maintain a
cancer stem cell phenotype speciﬁcally in triple-negative breast cancer
cells through its interaction with NANOG and focal adhesion kinase
(FAK). c Cx32 binds to the scaffold protein discs large homologue 1
(Dlgh1) and may control cell proliferation in liver cells through its
interaction with and maintenance of Dlgh1 at the plasma membrane.
The interaction of Dlgh with Cx43 has also been associated with
cancer progression through a mechanism involving the oncoprotein E6
(see section “Connexins and tumour viruses”). d Cx50 interacts with
and promotes auto-ubiquitination and the subsequent degradation of
Skp2, a key negative regulator of the cyclin-dependent kinase (CDK)
inhibitor p27. a–d To complicate this scenario, the phosphorylation of
connexins modiﬁes their binding afﬁnities to various protein partners.
For instance, c-Src phosphorylation affects the binding of several
Cx43 partners. GJIC, gap junction intercellular communication
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surrounding skin keratinocytes is signiﬁcantly correlated
with malignant features such as tumour thickness and, in the
case of Cx26, metastasis [66]. In lung cancer, the reduced
expression of Cx43 mRNA in adjacent normal lung tissue
(due to promoter methylation) is signiﬁcantly correlated
with nodal involvement, suggesting that Cx43 could be a
marker for micrometastasis in non-small cell lung cancer
[8]. Recently, Cx30.3 (GJB4) mRNA expression was
shown to be increased in lung tumours, with the levels in
blood buffy coat samples serving as a biomarker for diag-
nosis and poor prognosis [67]. Mechanistically, Cx30.3 was
shown to promote tumour growth and induce chemoresis-
tance via the MET-induced activation of Src.
As shown in Table 1, Cx26 mRNA expression is asso-
ciated with a poor prognosis in various cancers. For
example, high levels of Cx26 mRNA are associated with
reduced overall survival in pancreatic cancer (P < 0.001)
[68]. Microarray analysis (and conﬁrmatory quantitative
real-time polymerase chain reaction analysis) of breast
cancer samples show the upregulation of Cx26 during
progression from ductal carcinoma in situ to invasive ductal
carcinoma [69]. At the protein level, Cx26 is detected in the
invasive carcinoma foci [69]. In agreement with these
ﬁndings, Cx26 was recently found to drive CSC self-
renewal in triple-negative breast cancer [62].
At the DNA level, few studies have provided an insight
into the role of connexins in cancer. Mutations in Cx43
have been described in advanced metastatic colon cancer
lesions [70]. However, current large-scale genetic studies
and analytical tools (e.g. Intogen https://www.intogen.org
or COSMIC http://cancer.sanger.ac.uk/cosmic) suggest
relatively low mutation rates in connexin-encoding genes
and, based on genetic data, none of the 21 connexin genes
are classiﬁed as tumour suppressors or oncogenes. Never-
theless, individual genetic studies merit follow-up. For
example, the C1019T polymorphism in GJA4 (encoding
Cx37) is associated with Helicobacter pylori infection in
patients with gastric cancer [71]. In glioma, GJB6 (encoding
Cx30) was deleted in 25.8% of the 751 analysed tumours
and was mutated in 15.8% of 158 tumours [51]. However,
Table 1 Signiﬁcant associations between connexin mRNA expression and cancer prognosis
Connexin (gene) Cancer Clinical relevance Survival,a % alive P value (best separation)
Cx26 (GJB2) Renal U H= 52% (n= 188), L= 73% (n= 689) 5.98E-04
KIRC U H= 46% (n= 130), L= 70% (n= 398) 7.79E-05
Pancreatic U H= 15% (n= 86), L= 40% (n= 90) 2.90E-04
Glioma U H= 0% (n= 39), L= 11% (n= 114) 5.98E-04
Lungb U H= 43% (n= 795), L= 49% (n= 199) 6.25E-04
LUADb U H= 33% (n= 330), L= 53% (n= 170) 1.45E-05
Cx30.3 (GJB4) Pancreatic U H= 15% (n= 139), L= 66% (n= 37) 3.24E-05
Cervical F H= 74% (n= 181), L= 52% (n= 110) 5.48E-04
Cx31 (GJB3) Pancreatic U H= 15% (n= 70), L= 37% (n= 106) 7.56E-05
Lungb U H= 44% (n= 709), L= 45% (n= 285) 4.56E-04
LUADb U H= 18% (n= 107), L= 45% (n= 393) 3.54E-08
Cx31.1 (GJB5) Pancreatic U H= 0% (n= 66), L= 42% (n= 110) 1.54E-04
Cx32 (GJB1) Renalb F H= 77% (n= 451), L= 61% (n= 426) 2.85E-06
KIRCb F H= 75% (n= 284), L= 50% (n= 244) 4.88E-08
Cx37 (GJA4) Renalb U H= 67% (n= 700), L= 80% (n= 177) 7.44E-04
KIRCb F H= 68% (n= 417), L= 48% (n= 111) 8.57E-04
KIRPb U H= 58% (n= 77), L= 82% (n= 208) 1.07E-05
Liver F H= 53% (n= 225), L= 39% (n= 140) 3.28E-04
Cx43 (GJA1) Stomach U H= 14% (n= 98), L= 45% (256) 4.99E-05
KIRCb F H= 68% (n= 409), L= 45% (119) 2.60E-04
Cx45 (GJC1) Renal U H= 63% (n= 562), L= 80% (n= 316) 3.55E-08
Urothelial U H= 34% (n= 286), L= 58% (n= 120) 7.83E-04
aSurvival: percentage of patients alive after 3 years for glioma and 5 years for all other cancer types. The table and the P values are based on a best-
ﬁt model in which patient numbers (n) are stratiﬁed into high (H) and low (L) connexin expression groups
bCancer subtype-speciﬁc evidence (i.e. only some subtypes correlate). All data are taken from the Human Protein Atlas (https://www.proteinatlas.
org/pathology) after analysis by Uhlen et al. [63]. Fragments per kilobase million (FPKM) cut-off (median separation) is set to 1
F connexin expression is favourable for outcome, U connexin expression is unfavourable for outcome, H high expression, L low expression, n
number of patients, LUAD lung adenocarcinoma, KIRC kidney renal clear cell carcinoma, KIRP kidney renal papillary cell carcinoma
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again, the overall patient survival was not correlated with
the presence of GJB6 deletions (517 tumours from TCGA
and 67 tumours from REMBRANDT) or GJB6 mRNA
expression (in patients from TCGA). However, at the pro-
tein level, high Cx30 expression adversely inﬂuenced the
survival (Table 2).
A number of immunohistochemical studies of connexins
in cancer—most on Cx26 and Cx43—have described spe-
ciﬁc prognostic associations. As with mRNA-expression
studies, connexin protein expression has been associated
with both good and poor prognoses. The studies speciﬁcally
reporting the signiﬁcant ﬁndings related to patient survival
are summarised in Table 2.
In accordance with mRNA-based studies, the expression
of different connexins at the protein level can have an
opposing prognostic value depending on cancer type, cancer
subtype and connexin isoform. For example, in the same
breast cancer series, elevated Cx43 and Cx30 levels have
been associated with improved and worse breast cancer
outcomes, respectively [64]. Another shared ﬁnding between
the mRNA and protein studies is the observation that high
levels of Cx26 are associated with a poor prognosis in most
studies/cancers (Tables 1 and 2). This observation is sup-
ported by additional studies evaluating tumour histology or
aggressiveness, but not the overall survival, including those
of thyroid cancer [72] and bladder cancer [73]. Connexin
expression has also been proposed as a diagnostic aid in
relation to speciﬁc tumour subtypes. In gastric cancer, Cx30
was proposed as a potential marker for an intestinal-type
cancer phenotype, and the negative expression of Cx30
correlates with a more advanced T grade ( < 0.0001), N
grade (0.0123) and tumour stage (0.0014) [74]. An asso-
ciation between the expression level of connexins and
metastasis can be found for several cancer types. For
instance, Cx43 expression is reduced in primary gastric
cancer but increased in matched metastatic lymph nodes
[75]. It should also be noted that, in a number of studies,
connexin proteins were overexpressed but mislocalised in
the cytoplasm. Prominent examples include Cx26 in pan-
creatic [76] and colon [77] cancer, and Cx43 and Cx32 in
prostate cancer [78]. Nuclear Cx43 has also been reported in
a number of tumours (e.g. colon cancer [38] and gliomas
[79]). It remains to be seen how this mislocalisation corre-
lates with a recent report showing that nuclear Cx43 (or the
CT alone) can act as a direct nuclear transcription factor that
induces the expression of N-cadherin, an important regulator
of processes including epithelial-to-mesenchymal transition
and cell migration [80].
In summary, connexins are potential prognostic markers
in cancer, but a number of limitations need to be addressed
before any clinical application. The fact that connexins have
both pro- and antitumourigenic properties and are asso-
ciated with both good and poor prognoses, depending on
cancer stage and type/subtype as well as connexin isoform,
complicates their clinical applicability. Standardisation is
also difﬁcult in terms of reliable antibodies and evaluation
parameters such as the quantiﬁcation of subcellular con-
nexin localisation (e.g. membrane vs cytoplasm), which can
signiﬁcantly inﬂuence the prediction of the clinical
outcome.
Targeting of connexins in cancer:
therapeutic opportunities and challenges
The complex and multifunctional role of connexins in
cancer provides a wide spectrum of therapeutic opportu-
nities and challenges. Increasing numbers of drugs, peptides
and RNAi approaches are available to inhibit or enhance
GJIC, hemichannel activity or connexin protein-signalling
activity. Below, we highlight a selection of in vivo studies
demonstrating that the cancer phenotype is altered as a
direct consequence of such an experimental targeting of
connexins.
Modulation of connexin expression and GJIC
The restoration of GJIC and/or connexin expression has
long been a potential therapeutic strategy. GJIC can be
augmented either by enhancing the permeability of existing
gap junctions or by increasing the expression of connexins
and thereby elevating the number of open gap junction
channels [81]. Many fungal and plant-based compounds, as
well as an increasing number of synthetic chemical com-
pounds, either increase GJIC or prevent the loss of GJIC in
response to cellular exposure to tumour promoters, which is
often associated with reduced tumour growth in vivo.
Compounds shown to modify connexins or GJIC and affect
the tumour phenotype in vivo are summarised in Table 3. It
is worth noting that many chemotherapeutic agents also
increase connexin expression and/or GJIC [82]. For exam-
ple, docetaxel increases Cx43 expression in murine salivary
gland carcinoma to reduce tumour growth [83]. This has
implications for combinatorial effects in cancer therapy.
However, because connexins under speciﬁc conditions
can facilitate malignant features, in particular, metastasis or
growth of metastases [2], there are situations in which the
blockade of GJIC or other functions of connexins may offer
distinct therapeutic opportunities. The inhibition of GJIC can
be achieved through a number of different mechanisms
(Table 3 and recent comprehensive reviews [5, 84]). Despite
their non-speciﬁcity, many chemical gap junction channel
inhibitors have been extensively used, even in vivo. For
instance, the GJIC blocker oleamide (a fatty-acid derivative)
reduces the formation of pulmonary and hepatic metastatic
foci and increases the overall survival of mice injected
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intravenously with MDA-MB-231 breast cancer cells [85].
Mechanistically, oleamide-induced loss of heterologous
GJIC between tumour cells and endothelial cells was sug-
gested to interfere with cancer-cell extravasation. Using a
brain metastasis mouse model, Massagué and colleagues
recently demonstrated the potent growth inhibition of brain
metastases from breast and lung cancer cells in response to
blockade of heterologous GJIC between the cancer cells and
astrocytes [50]. Inhibition of heterologous GJIC was
achieved either by the knockdown of Cx43 expression or by
the use of the gap junction channel inhibitors tonabersat or
meclofenamate, which pass the blood–brain barrier [50].
Tonabersat has been used as a migraine prophylaxis drug,
whereas meclofenamate is an FDA-approved anti-inﬂam-
matory drug for oral administration. Mechanistically, these
GJIC inhibitors seem to inhibit tumour growth by blocking a
cGAMP-mediated signalling cascade that orchestrates para-
crine signalling between host and tumour cells [50]. Con-
sequently, as the ﬁrst cancer clinical trial in which GJIC is
speciﬁcally being targeted, meclofenamate is being tested in
human patients with recurrent or progressive brain metas-
tasis (https://clinicaltrials.gov/ct2/show/NCT02429570?id=
NCT02429570&rank=1&load=cart). Recently, a novel role
of Cx43-based gap junctions was also identiﬁed in breast
cancer bone metastasis [86]. Gap junctions were found to
mediate calcium ﬂow from osteogenic cells to the cancer
cells. Blocking such heterocellular intercellular calcium
transfers from the osteogenic niche to cancer cells, by gap
junction inhibitors (carbenoxelone and arsenite trioxide)
or by the ablation of Cx43 in either the osteogenic cells or
the cancer cells, prevented bone metastasis progression in
mice [86].
Thus, many of the studies reporting the inhibitory effects
on tumour growth upon inhibition of GJIC mechanistically
relate this effect to a loss of heterologous GJIC between
tumour cells and cells in their microenvironment (as
reviewed in [50, 85] and discussed elsewhere in this
manuscript). Other successful strategies include the peptide-
mediated inactivation of Cx40 in endothelial cells causing
the inhibition of tumour angiogenesis in vivo and subse-
quently decreased tumour growth [87] (see Table 3 and
section “Emerging concepts”). αCT1, a peptide that blocks
ZO-1 and potentially other proteins from interacting with
the Cx43-CT (see section “Targeting of connexins in can-
cer”), has been demonstrated to prevent temozolomide
resistance in human glioblastoma cell lines [65]. The use of
peptides arguably provides for a more speciﬁc targeting
compared with the more general chemical GJIC inhibitors
and may reduce potential adverse effects. Cx43-blocking
antibodies also reduce tumour growth in murine models.
Notably, the intravenous administration of a monoclonal
antibody targeting the second extracellular loop of Cx43
reduces glioma growth and survival of experimentalTa
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Connexins in cancer: bridging the gap to the clinic
animals when used alone [88] or in combination with
standard cancer therapy approaches [89]. The same anti-
body has been used as a guidance system to deliver diag-
nostic markers or therapeutic compounds, such as cisplatin,
to Cx43-positive high-grade gliomas [90, 91].
Targeting of hemichannels
Connexin hemichannels are normally closed but, when
activated, they can release autocrine and paracrine signals,
such as NAD+, glutamate or ATP, that can affect cell
proliferation and survival [92]. For instance, ATP release
activates the AKT/AMPK/mTOR signalling pathway, thus
linking hemichannel activity with cell proliferation and
survival [93]. Several lines of evidence suggest that Cx43
hemichannels are involved in promoting tumour growth.
Antibodies against the second extracellular loop domain of
Cx43, which blocks hemichannels [94], reduce glioma
tumours generated with C6 cells in rats [89]. Similarly, the
peptide αCT1 increases the sensitivity to chemotherapy in
glioma cells, possibly through the inhibition of Cx43
hemichannel activity [65]. On the other hand, Cx43 hemi-
channels in osteoblast bone cells may provide an intrinsic
self-defence mechanism against breast cancer metastasis
[95]. Among the other molecules released by Cx43 hemi-
channels in osteoblasts, ATP acts as a paracrine signal that
triggers an inﬂammatory cascade to inhibit the migration,
invasion and anchorage-independent growth of breast can-
cer cells [96]. Consequently, the antibody blockade of
osteocyte Cx43 hemichannels increases bone metastasis in
mice [95]. Collectively, these data suggest that Cx43
hemichannel activity in healthy tissue cells may have a
beneﬁcial effect by preventing metastasis, whereas hemi-
channels in tumour cells may favour their growth.
Targeting of the connexin interactome
Connexins interact with a wide variety of proteins that,
independent of channel activity, can affect cancer cell
phenotype, including cell growth, migration and differ-
entiation (Fig. 3; recently reviewed in refs. [97, 98]). Stra-
tegies that mimic, promote or disrupt some of these speciﬁc
interactions could be used in cancer therapy. The fact that
Cx43-CT is a disordered region favours the use of mimetic
peptides that can restore or interfere with its functions. In
tumour cells with low levels of Cx43, the restoration of
Cx43 function may reduce cell proliferation. In glioma
cells, this occurs via the inhibition of the oncogenic activity
of c-Src [99]. The mechanism by which Cx43 reduces c-Src
activity resides in a short region of Cx43-CT (266–283) that
acts as a docking platform for c-Src together with its
endogenous inhibitors PTEN and CSK [43]. Notably, the
mimetic peptides of this region fused to the TAT-
penetrating sequences (TAT-Cx43266-283) can mimic the
anti-oncogenic effect of Cx43 in glioma cells such as pri-
mary GSCs [55, 100].
In contrast, some proteins may favour cell growth or
migration upon interaction with Cx43-CT. For instance,
Cx43 may interact with p21-activated protein kinase 1,
which activates the MAPK p38 to increase the migration of
HeLa cells [101], or may compete with tubulin–Smad2/3
interaction causing Smad2/3 release [102] (Fig. 3). Other
Cx43-interaction partners regulate the Cx43 protein level or
subcellular localisation. Disruption of these interactions
may have therapeutic potential. αCT1 is a Cx43-CT
mimetic peptide that comprises the ZO-1 PDZ-binding
domain of Cx43 fused to a cell-penetration sequence, which
was designed as a tool to disrupt the interaction between
endogenous ZO-1 and Cx43 [103]. Consequently, αCT1
can increase the size of Cx43 gap junction plaques and
increase GJIC to the detriment of hemichannel activity
[104]. αCT1 increases the sensitivity of glioma cells to
temozolomide [65] and of breast cancer cells to tamoxifen
and lapatinib [105]. In an ongoing clinical trial in dogs with
naturally occurring high-grade glioma, a slow controlled
release of αCT1 encapsulated in a polymer is being tested in
combination with chemotherapy [106].
Enhanced and synergistic therapeutic effects of
connexin targeting
The bystander effect: kiss-of-life or kiss-of-death?
The bystander effect underpins a key therapeutic strategy in
anticancer approaches and signiﬁcantly enhances suicide
gene therapy strategies [107]. A well-established suicide
gene therapy approach involves the viral transduction of the
herpes simplex virus (HSV) thymidine kinase (TK) gene
into cancer cells [108]. The viral TK enzyme phosphor-
ylates the nucleoside analogue ganciclovir (GCV), which
causes chain termination during DNA replication and leads
to tumour cell death. Many reports in the 1990s revealed
that neighbouring tumour cells that were not transduced
with the TK/GCV suicide system also died. This was
demonstrated in vitro and in vivo to be due to the GJIC-
mediated transfer of activated GCV and/or other toxic
metabolites [109, 110]. This led to the hypothesis that the
induction of connexin expression or re-establishment of
GJIC might potentiate the bystander effect [111], a claim
substantiated early on, both in vitro [109, 112] and in vivo
[113]. This theory is supported by many studies (e.g. refs.
[114–117]), including a recent one in breast cancer [118]
and liver cancer, in which the co-expression of Cx43 and
SUMO1 in liver CSCs increased GJIC and their sensitivity
to HSV-TK/GCV therapy in vitro and in vivo [57]. How-
ever, other studies reported no evidence for a GJIC-
T. Aasen et al.
mediated bystander effect [119]. Moreover, GJIC can pro-
tect transduced cells from the toxic active GCV by allowing
effective drug dilution throughout the cell, preventing cell
death in a so-called “Good Samaritan” effect [120, 121].
The bystander effect is important in a wide range of
circumstances other than suicide gene therapy. Notably,
some chemotherapeutic drugs or radiation-induced metabo-
lites such as DNA damage-induced sensing/signalling
molecules or cytoplasmic irradiation responders (reactive
oxygen species, reactive nitrogen species, Ca2+ and cyto-
kines) can also transmit through GJIC, inducing a bystander
effect [120]. However, the strength and type of the signal
may have distinct and opposing effects: (1) toxic signals kill
neighbouring cells (which may be tumour cells or healthy
cells) or (2) toxic signals are diluted into neighbouring cells,
favouring the survival of the targeted cells. Importantly, this
implicates GJIC in coordinating cellular and tissue responses
to carcinogens, radiation and chemotherapies and leads to
the possible strategies (via both enhanced or blocked GJIC)
for either protecting undamaged non-targeted cells against
such signals or potentiating the signals in order to kill
tumour cells. Application of this knowledge to other aspects
of connexin cancer biology is important.
Need for combinatorial therapy
Within the ﬁeld of cancer therapy, there is a general con-
sensus on the need for rational combinatorial targeted
therapy. Synergistic effects on cancer cell growth as a result
of enhanced connexin expression or GJIC in combination
with drugs targeting other cellular processes have been
described in many studies [122–127] (Table 3). For
instance, kanglaite, a natural plant seed compound that
upregulates Cx43 expression, sensitises colorectal cancer
cells to Taxol [124]. Simvastatin (a statin) induces GJIC and
enhances the effect of platinum-based chemotherapeutic
drugs [126]. In addition, protection can be provided against
the non-desired cytotoxic effects of cisplatin on healthy
cells, including reproductive testicular Sertoli cells [127].
Such dual kiss-of-life/kiss-of-death bystander effects can
contribute to the overall chemotherapeutic outcome on
multiple levels. It also poses a therapeutic challenge. The
putative positive and negative effects such therapies can
provide in relation to tumour growth must therefore be
carefully assessed in order to avoid a possible worsening
rather than an improvement of the clinical outcome.
The therapeutic response of cancer cells can also be
affected by the direct overexpression of connexins, in an
isoform-speciﬁc manner. For instance, Cx43 overexpression
can enhance the sensitivity to common chemotherapeutic
drugs such as doxorubicin, ﬂuorouracil and oxaliplatin in
human gastric cancer cells [128], etoposide, paclitaxel and
doxorubicin in glioma cells [129], and artesunate in MCF-7
breast cancer cells [130]. Cx32 potentiates the cytotoxicity
of vinblastine and Src inhibitors in renal cell carcinoma
cells [131], whereas Cx26 increases the effect of cisplatin in
human bladder cancer cells [132] and of doxorubicin in
prostate cancer cells [133]. Both channel-dependent and
-independent mechanisms have been suggested to underlie
this effect [130, 134].
In other contexts, connexins can have an inverse effect
with respect to drug sensitivity. Reduced Cx43 expression
is associated with increased drug sensitivity in glioma cells
[52, 134–136], whereas the upregulation of Cx26 is asso-
ciated with geﬁtinib resistance in lung cancer cells [137].
The speciﬁc inhibition of Cx46-mediated GJIC in GSCs
attenuates proliferation, self-renewal and tumour growth
and synergises with temozolomide to induce apoptosis
[138]. There is also in vivo evidence to support this
dichotomy in relation to therapeutic efﬁcacy. For instance,
shRNA-mediated knockdown of Cx43 or inhibition of GJIC
by meclofenamate and tonabersat strongly potentiates the
effect of carboplatin-based chemotherapy on brain metas-
tases from breast and lung carcinoma cells [50]. Moreover,
the efﬁcacy of tumour necrosis factor-related apoptosis-
inducing ligand therapy is enhanced when combined with
the GJIC inhibitor carbenoxolone in an intracranial glioma
model [136]. The combined use of tumour necrosis factor-
related apoptosis-inducing ligand and carbenoxolone could
offer a favourable alternative for the treatment of glioma,
particularly considering the low cytotoxic nature of carbe-
noxolone. Notably, carbenoxolone, as well as peptides tar-
geting Cx43, attenuates cancer-induced bone pain [139],
highlighting another facet of cancer care in which connexins
can be further explored.
Emerging concepts
Role of connexins in tumour microenvironment
That GJIC between normal cells and tumour cells (hetero-
logous GJIC) can inhibit the growth of tumour cells was
shown in the mid 1980s by Loewenstein and colleagues
[140]. This phenomenon has since been demonstrated in
many cancer types and model systems, as recently reviewed
[141]. Heterologous GJIC between tumour cells and the
cells within their microenvironment (Fig. 4) has been linked
to both positive and negative effects on tumour progression
and therapy resistance.
Communication between cancer cells and immune cells
Tumour cells deliver antigenic peptides through gap junctions
to dendritic cells, and this cross-presentation is associated
with enhanced immune-mediated tumour elimination.
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Presentation of antigenic peptides between melanoma cells
and dendritic cells increases the melanoma-speciﬁc T-cell
response [142]. The infection of melanoma tumours with
Salmonella bacteria induces Cx43 expression, which enhan-
ces the antigen presentation into inﬁltrating dendritic cells,
activating an antitumour response [143]. Cx43-mediated
GJIC may also improve the immune surveillance of
tumours via the activation of natural killer cells [144, 145].
GJIC-mediated transfer of miRNAs from immune cells to
hepatocarcinoma cells seems to inhibit tumour growth [146].
These studies (and others, as reviewed recently [141]) are of
particular interest in relation to immunotherapy and tumour
vaccines [141]. Connexins also regulate many other functions
within the immune and lymphatic systems, which awaits an
additional analysis [147].
Angiogenesis and communication between cancer cells and
endothelial cells
Angiogenesis, the formation of new capillaries from pre-
existing blood vessels, is required for cancer progression
[148]. Overexpression of Cx43 in melanoma and breast
cancer cells suppresses tumour angiogenesis [28, 149]. In
accordance with these ﬁndings, Cx43 knockdown in mel-
anoma cells increases vessel density [149]. The silencing of
Cx43 in breast cancer cells results in increased vascular
endothelial growth factor expression and decreased throm-
bospondin expression [29]. In contrast, the overexpression
of Cx26 or Cx43 in breast cancer cells is associated with the
upregulation and secretion of IL-6 and MCP-1, which
inhibit endothelial cell tube formation in vitro and tumour
vascularisation in vivo [28].
Endothelial connexins also play important roles in
tumour angiogenesis. The knockdown of endothelial Cx37,
Cx40 or Cx43 or the pharmacologic inhibition of GJIC
diminishes the angiogenic sprouting of endothelial cells in
in vitro studies [150]. A recent work using a combination of
different in vitro, ex vivo and in vivo models has shown that
targeting of endothelial Cx40 decreases tumour growth by
reducing angiogenesis and improving vessel perfusion [87].
This was demonstrated both in mouse endothelial-speciﬁc
Cx40 knockout models and by the injection of the speciﬁc
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Fig. 4 Connexins and the tumour stroma. GJIC can occur between
cancer cells or in a heterocellular manner between cancer cells and
nearby cells such as noncancerous epithelial tissue cells and stromal
cells, including cancer-associated ﬁbroblasts, immune cells and vas-
cular and lymphatic endothelial cells. In addition, there is crosstalk via
the hemichannel release of autocrine and paracrine signals. These
signals inﬂuence tumour growth both positively and negatively in a
context-dependent manner and help to regulate apoptosis, prolifera-
tion, invasion, intravasation and extravasation. In addition, connexins
are thought to be implicated in other communication forms, as a part of
tunnelling nanotubes (microtubes) or extracellular vesicle function
(e.g. exosomes). Other tumours, or parts of tumours, are devoid of
GJIC and may or may not express connexins at high levels in the
cytoplasm or nucleus, thus escaping the direct GJIC with surrounding
cells. This may be associated with a reduced polarity and cell–cell
adhesion. The beneﬁts and drawbacks of maintained GJIC are likely
tissue and stage dependent. An understanding of this complex network
of signals is essential to move forward with additional therapeutic
strategies of targeting connexins in cancer. GJIC, gap junction inter-
cellular communication
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peptide 40Gap27 that binds to the extracellular loop of Cx40
and blocks channel activity [151].
Because endothelial and myoendothelial gap junctions
are fundamentally important for a coordinated vessel
response over longer distances [152, 153], a therapeutic
approach focused on vascular connexins would be con-
ceivable through the specialised targeting of tumour vessels
in combination with anti-angiogenic strategies.
There is also evidence of direct communication between
tumour cells and endothelial cells (Fig. 4). Recent studies
have demonstrated GJIC-mediated heterotypic exchange of
microRNAs between cancer cells and endothelial cells.
Notably, endothelial cells deliver miR-145–5p to colon
cancer cells via gap junctions, causing the upregulation of
Cx43 expression and reduced angiogenesis [154]. More-
over, the inhibition of GJIC by carbenoxolone blocks the
interchange of speciﬁc cancer-associated microRNAs
between human microvascular endothelial cells and a
human glioma cell line [155].
As mentioned, Cx26 may facilitate extravasation into the
endothelium during metastasis [47], and Cx43 enhances
attachment and diapedesis into endothelial cells in models
of breast cancer [48, 156] and melanoma metastasis [157].
Heterocellular Cx43-mediated GJIC between gastric cancer
cells and mesothelial cells may facilitate diapedesis during
peritoneal metastasis [75]. Using zebraﬁsh and chicken
embryo models of brain metastasis, Stoletov et al. [158]
determined that Cx26 and Cx43 acted in the early initiation
stages of metastatic lesion formation in association with
vasculature. RNAi-mediated depletion of Cx26 and Cx43 in
melanoma and breast cancer cells, respectively, or phar-
macological inhibition of GJIC using carbenoxolone, was
found to inhibit brain colonisation by blocking tumour cell
extravasation and blood vessel co-option [158]. Such
crosstalk between cancer cells and blood vessels may also
occur via hemichannels, such as the one through ATP
release, which ultimately can stimulate angiogenesis [159].
There is also evidence that GJIC facilitates cancer cell
migration through the lymphatic endothelium [160]. Thus,
blockade of connexin-mediated heterocellular communica-
tion is emerging as a potential viable strategy for reducing
metastasis. Indeed, the Cx43 channel blocker oleamide has
antimetastatic properties in the MDA-MB-231 breast cancer
cell line, presumably due to the inhibition of extravasation
into the endothelium [85].
Communication between cancer cells and astrocytes
Connexins can also elicit pro-tumourigenic effects in brain
tumours. Cx43 expression and heterologous GJIC between
malignant glioma cells and reactive astrocytes enhance cell
invasion into the brain parenchyma [161–163], which may
in part occur through microRNA-mediated signalling [164].
Glioma cells can also become more resistant to che-
motherapy- or radiotherapy-induced cell death through both
homocellular and heterocellular GJIC pathways [51, 53,
165], as well as via Cx43-speciﬁc GJIC-independent
mechanisms [166]. GJIC between reactive astrocytes and
melanoma cells protects against chemotherapy through the
sequestration of calcium [34]. A recent study has described
another signalling network between astrocytes and breast
and lung carcinoma cells involving cGAMP and the sti-
mulator of interferon genes (STING) pathway (see section
“Modulation of connexin expression and GJIC”), and the
inhibition of GJIC or Cx43 expression was found to sub-
stantially reduce the brain metastatic burden and enhance
chemotherapy efﬁcacy [50]. In summary, GJIC between
tumour cells and astrocytes promotes colonisation, resis-
tance to chemotherapy and survival of tumour cells in the
brain [34, 50, 164, 167]. Targeting of this axis may provide
clinical beneﬁts.
Connexins and tumour viruses
An estimated 10–12% of human cancers worldwide are
caused by viruses and 4.5% are caused by the so-called
“high-risk” human papillomaviruses (HPVs) [168]. Rous
sarcoma virus-infected ﬁbroblasts display a loss of GJIC,
and its oncogene pp60v-src causes Cx43 tyrosine phosphor-
ylation and reduced Cx43 levels [169]. Similarly, SV40
large T antigen-transformed normal invasive trophoblasts
lose GJIC and display reduced Cx43 levels [169]. Human
cytomegalovirus is not recognised as a tumour virus.
However, human cytomegalovirus proteins have been
detected at high levels in gliomas and can downregulate
Cx43 and GJIC [170]. These data suggest that a range of
viruses inhibit GJIC.
In 1969, McNutt and Weinstein recognised that gap
junction plaques are lost in cervical cancers [171]. Subse-
quently, cervical cancers were shown to be caused by HPVs
[172]. Reduced connexin expression can occur in pre-
neoplastic cervical lesions [173], perhaps in part due to the
loss of epithelial differentiation. On the other hand, loss of
Cx43-mediated GJIC occurs as a direct consequence of
HPV-associated cancer progression [174], and HPV infec-
tions alter multiple connexins at the transcript level [175].
High-risk HPVs encode two oncoproteins, E6 and E7,
which are highly expressed in cervical cancer. E6 alters
Cx43 trafﬁcking to the plasma membrane either through its
ability to alter cell signalling pathways or through its
interaction with the Cx43 partner protein Dlgh1 [42, 176].
HPV E5, a subsidiary oncoprotein, also downregulates
Cx43 and GJIC when overexpressed in keratinocytes [177].
Upon infection, viral DNA is detected by cyclic GMP-
AMP synthase, which synthesises the STING activator
cGAMP to induce an antiviral state through intercellular
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transmission. Connexins are responsible for the bystander
immunity to viruses [178], and so viruses may have evolved
means to inactivate this response by regulating connexins, a
feature that could be exploited therapeutically.
Role of connexins in long-distance cell–cell
communication
Tunnelling nanotubes
Tunnelling nanotubes (TNTs) are thin actin-based mem-
brane bridges that connect cells over distances of up to
several cell diameters [179]. These structures allow for the
intercellular transfer of microRNAs, proteins and cyto-
plasmic organelles, including mitochondria. The presence
of connexin channels interposed in the nanotube connec-
tions permits long-distance electrical coupling between cells
[179, 180]. TNTs are formed between various cancer cell
types in vitro [179]. TNTs between malignant cells and
stromal cells may be involved in chemoresistance [181] and
tumour–stromal crosstalk [182, 183]. Recently, Osswald
et al. [184] demonstrated in vivo that glioma cells form a
network of TNT-like structures called microtubes that
contribute to their invasion in the brain. Cx43-containing
gap junctions within this network were suggested to turn the
tumour into a syncytium of interconnected cells that is
highly resistant to radiation therapy, presumably by dis-
tributing calcium between cells to prevent apoptosis upon
radiation-induced release of intracellular calcium [184].
Extracellular vesicles
Extracellular vesicles (EVs), which constitute micro-
vesicles, apoptotic bodies and exosomes, are membrane-
based structures that can carry and deliver bioactive mole-
cules, including proteins and nucleic acids, from one cell to
another. This form of cell-to-cell communication can occur
over very long distances and efﬁciently cross the blood–
brain barrier. EVs released by tumour cells and cancer-
associated ﬁbroblasts affect cancer progression by trans-
ferring molecules inﬂuencing tumour initiation, angiogen-
esis, metastasis and drug resistance [185]. Functional Cx43
channels were recently identiﬁed in the membrane of EVs
[186]. In melanoma, Cx32, Cx43 and Cx45 were detected
in these structures [187]. Connexins facilitate the transfer or
exchange of EV contents with target cells, possibly by
improving fusion events with cells [186]. This may be
exploited therapeutically to improve drug delivery. How-
ever, in one mouse model, delivery of doxorubicin as a
chemotherapeutic agent was not improved in the presence
of Cx43 in EVs, although it strikingly reduced cardiotoxi-
city [188]. In addition, Cx43 phosphorylation through
extracellular signal-regulated kinase signalling induces
exosome release upon traumatic brain injury [189]. Thus, it
seems clear that connexins are involved in the formation
and function of EVs, but the therapeutic implications await
further works.
Concluding remarks and future perspectives
Substantial knowledge on how gap junctions contribute to
cancer has accumulated since the seminal work by Loe-
wenstein and Kanno demonstrated a loss of electrical cou-
pling in liver cancer more than 50 years ago [7]. Connexins
predict the prognosis of a number of cancers, although the
lack of established protocols and conﬁrmatory independent
studies has limited their clinical utility. Several promising
studies using an expanded set of tools to modulate connexin
or gap junction function have demonstrated potent anti-
tumoral effects. As we decipher their cancer type- and
stage-speciﬁc roles, signiﬁcant progress towards targeting
of connexins and gap junctions in a patient-speciﬁc ther-
apeutic setting can be expected. An ongoing clinical trial
testing the GJIC inhibitor meclofenamate in patients with
carcinoma metastasis to the brain underpins this positive
outlook (https://clinicaltrials.gov/ct2/show/NCT02429570?
id=NCT02429570&rank=1&load=cart). Nevertheless,
there are signiﬁcant challenges that remain to be addressed.
The fact that connexins can be both anti- and pro-
tumorigenic is of particular concern. For example, would
enhancing GJIC or connexin expression in a primary
tumour run a risk of more efﬁcient metastatic spread or
growth? Does inhibition of GJIC in patients with metastasis
increase the risk of further tumour dissemination or re-
activated tumour growth in sites harbouring dormant
tumour cells? Currently, this clinical problem can only be
addressed by hypothetical risk assessment and thus further
research, including an extensive use of in vivo models and a
careful follow-up of ongoing clinical trials, is required.
Currently, only a few of the 21 connexin isoforms have
been characterised in terms of their role in cancer. Addi-
tional studies are necessary to elucidate the GJIC-dependent
and -independent mechanisms by which the various con-
nexins positively or negatively affect cell growth, differ-
entiation, invasion and other important cancer-associated
features. In this context, more speciﬁc tools will be required
to target the different functions of connexins. Further efforts
need to be devoted to the identiﬁcation of more speciﬁc
connexin inhibitors. The use of speciﬁc peptides and pep-
tidomimetics have shown a great promise towards this.
However, their side effects must be carefully addressed
(particularly if applied systemically) due to the critical
functions of several connexins in various organs. Another
important challenge will be to dissect the molecular basis of
the regulation of the various connexin isoforms at the
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transcriptional, translational and post-translational levels
and to deﬁne how the dysregulation of these processes
contributes to aberrant levels or subcellular localisation of
connexins during various stages of cancer progression. The
identiﬁcation of solutions to these research challenges will
set the stage for new diagnostic and therapeutic advances.
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